<DOC>
	<DOCNO>NCT01854047</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy different dos regimen dupilumab patient moderate severe uncontrolled asthma Secondary Objective : To evaluate different dos regimen dupilumab patient moderate severe uncontrolled asthma , regard : - Safety tolerability - Dupilumab systemic exposure anti-drug antibody</brief_summary>
	<brief_title>An Evaluation Dupilumab Patients With Moderate Severe Uncontrolled Asthma</brief_title>
	<detailed_description>Total duration per participant approximately 43 week include screening period ( 14-21 day ) , randomize treatment period ( 24 week ) , post-treatment period ( 16 week ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : Patients physician diagnosis moderate severe , uncontrolled asthma ≥12 month , base Global Initiative Asthma ( GINA ) 2009 Guidelines : Existing treatment moderate highdose inhale corticosteroid / longacting beta2 agonist Forced expiratory volume ( FEV1 ) 40 80 % predict normal Juniper Asthma Control Questionnaire , 5question version ( ACQ5 ) score ≥1.5 Reversibility least 12 % 200 mL force expiratory volume ( FEV1 ) Has experience , within prior year : hospitalization , emergency urgent care visit systemic corticosteroid treatment worsen asthma Exclusion criterion : Patients &lt; 18 year Chronic obstructive pulmonary disease ( COPD ) lung disease ( eg , emphysema , idiopathic pulmonary fibrosis , ChurgStrauss syndrome , allergic bronchopulmonary aspergillosis ) impair pulmonary function test Chest Xray within 12 month screen visit screen visit clinically significant finding lung disease ( ) asthma Current smoker cessation smoking within 6 month prior Visit 1 Previous smoker smoke history &gt; 10 packyears The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>